Heath M D, Swan N J, Marriott A C, Silman N J, Hallis B, Prevosto C, Gooch K E, Skinner M A
Allergy Therapeutics Ltd, Dominion Way, West Sussex, BN14 8SA, UK.
Public Health England, PHE Porton, Porton Down, Salisbury, SP4 0JG, UK.
BMC Infect Dis. 2017 Mar 27;17(1):232. doi: 10.1186/s12879-017-2329-5.
Vaccination against seasonal influenza strains is recommended for "high risk" patient groups such as infants, elderly and those with respiratory or circulatory diseases. However, efficacy of the trivalent influenza vaccine (TIV) is poor in many cases and in the event of an influenza pandemic, mono-valent vaccines have been rapidly developed and deployed. One of the main issues with use of vaccine in pandemic situations is the lack of a suitable quantity of vaccine early enough during the pandemic to exert a major influence on the transmission of virus and disease outcome. One approach is to use a dose-sparing regimen which inevitably involves enhancing the efficacy using adjuvants.
In this study we compare the use of a novel microcrystalline tyrosine (MCT) adjuvant, which is currently used in a niche area of allergy immunotherapy, for its ability to enhance the efficacy of a seasonal TIV preparation. The efficacy of the MCT adjuvant formulation was compared to alum adjuvanted TIV and to TIV administered without adjuvant using a ferret challenge model to determine vaccine efficacy.
The MCT was found to possess high protein-binding capacity. In the two groups where TIV was formulated with adjuvant, the immune response was found to be higher (as determined by HAI titre) than vaccine administered without adjuvant and especially so after challenge with a live influenza virus. Vaccinated animals exhibited lower viral loads (as determined using RT-PCR) than control animals where no vaccine was administered.
The attributes of each adjuvant in stimulating single-dose protection against a poorly immunogenic vaccine was demonstrated. The properties of MCT that lead to the reported effectiveness warrants further exploration in this and other vaccine targets - particularly where appropriate immunogenic, biodegradable and stable alternative adjuvants are sought.
建议为婴儿、老年人以及患有呼吸系统或循环系统疾病等“高危”患者群体接种季节性流感疫苗。然而,三价流感疫苗(TIV)在许多情况下效果不佳,在流感大流行时,单价疫苗已迅速研发并投入使用。在大流行情况下使用疫苗的一个主要问题是,在大流行早期缺乏足够数量的疫苗来对病毒传播和疾病结果产生重大影响。一种方法是使用剂量节省方案,这不可避免地涉及使用佐剂来提高效力。
在本研究中,我们比较了一种新型微晶酪氨酸(MCT)佐剂的使用情况,该佐剂目前用于过敏免疫治疗的特定领域,以评估其增强季节性TIV制剂效力的能力。使用雪貂攻击模型来确定疫苗效力,将MCT佐剂配方的效力与明矾佐剂TIV以及未使用佐剂的TIV进行比较。
发现MCT具有高蛋白结合能力。在两组使用佐剂配制TIV的实验中,免疫反应(通过血凝抑制(HAI)效价测定)高于未使用佐剂的疫苗,尤其是在用活流感病毒攻击后。接种疫苗的动物的病毒载量(使用逆转录聚合酶链反应(RT-PCR)测定)低于未接种疫苗的对照动物。
证明了每种佐剂在刺激针对免疫原性较差的疫苗的单剂量保护方面的特性。导致所报道有效性的MCT特性值得在该疫苗及其他疫苗靶点中进一步探索——特别是在寻求合适的具有免疫原性、可生物降解且稳定的替代佐剂的情况下。